Ocular Therapeutix Inc. buy tamam
Start price
18.03.17
/
50%
€8.66
Target price
27.11.17
€18.04
Performance (%)
-63.75%
End price
27.11.17
€3.14
Summary
This prediction ended on 27.11.17 with a price of €3.14. Massive losses of -63.75% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ocular Therapeutix Inc. | 39.847% | 39.847% | 0.422% | -64.261% |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by tamam for this prediction
In the thread Ocular Therapeutix Inc. diskutieren
Ocur looks significantly undervalued,
given the likelihood of approval and potential of Dextenza. The company also has several other compounds in development. The company ended 2016 with just under $70 million in cash on hand and has a quarterly burn rate of less than $10 million. The shares currently sell for approximately one third the median analyst price target and I would not be surprised if the shares run up into that all-important July PDUFA date.
(Vom Mitglied beendet)